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Drosophila models of tauopathies have been developed by transgenically overexpressing the disease-associated forms of tau. In this
paper we report for the ﬁrst time that a recently developed Grape-Seed Polyphenolic Extract (GSPE) improves the eye phenotype
of a Drosophila eye model of R406W tau. GSPE-mediated improvements in this distinct in vivo neurodegeneration model for
protein misfolding/aggregation suggest that GSPE may have therapeutic value in disorders involving aberrant protein aggregation.
1.Introduction
Abnormal protein conformations resulting in misfolded
and/or abnormally aggregated protein species are a char-
acteristic feature of several neurodegenerative disorders.
For example, the microtubule-associated protein tau adopts
abnormal conformations resulting in protein helical ﬁla-
ment/immunopositive neuroﬁbrillary tangles (NFTs) and is
acharacteristicneuropathologicalfeatureinAlzheimer’sDis-
ease (AD), Pick’s disease, progressive supranuclear palsy, and
corticobasal ganglionic degeneration (CBD). Tau mutations
causefrontotemporaldementiawithParkinsonism-(FTDP-)
17, proving that tau dysfunction can directly promote
neurodegeneration [1].
Drosophila models using the transgenic Gal4/UAS system
[2] to overexpress disease-associated aggregation-prone pro-
teins have modeled aspects of tauopathy by overexpressing
R406W mutant tau [3, 4] and Huntington’s disease (HD)
by overexpressing Q93httexon1 [5–7]( f o rr e v i e w ,s e e[ 8]).
Overexpressing R406W in cells that form the eye (ey >
R406W) leads to dramatic reduction in or complete absence
of the eye. Eyes that do form demonstrate abnormal
morphology [4]; for review, see [8].
We previously reported that moderate consumption of
the red wine, Cabernet Sauvignon (Vitis vinifera), prevented
abnormal β-amyloid (Aβ) oligomerization coincidental with
a signiﬁcant attenuation of spatial memory impairment in
a mouse model of AD-type amyloid neuropathology [9].
Most importantly, we identiﬁed a polyphenolic compound
highly concentrated in grape-seed polyphenolic extract
(GSPE) as potentially responsible for the beneﬁcial role
of moderate consumption of red wine (Vitis vinifera)
[10, 11].
More recently, Ho et al. reported that, using an in
vitro aggregation assay, GSPE can signiﬁcantly inhibit tau
peptide Ac(306)VQIVYK(311) aggregation. Moreover, GSPE
can also disaggregate preexisting aggregated tau peptides
[12]. These results strongly suggest that GSPE might pro-
vide beneﬁcial disease-modifying activity in tau-associated
neurodegenerative disorders by modulating tau-mediated
neuropathologic mechanisms. In this paper, we use the
eye phenotype of a Drosophila model of mutant R406W
tau to further evaluate the beneﬁcial role of GSPE in
tau-mediated neuropathology in vivo. We report for the
ﬁrst time that treatment with GSPE signiﬁcantly beneﬁts
Drosophila phenotypes carrying mutant tau (R406W),f u r -
ther supporting the potential use in vivo of GSPE in abnor-
mal tau aggregation, as previously demonstrated in vitro
[12].2 International Journal of Alzheimer’s Disease
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Figure 1: GSPE attenuates R406W tau overexpression in the ﬂy eye. Male and female eye size diﬀers; male eyes are shown in (a)–(c), and
female eyes are shown in (d)–(f). Overexpression of R406W early in eye development results in a small or no eye ((b), (e)). Eyes that do not
overexpress R406W are shown in (a), (d) for comparison. GSPE treatment ameliorates the reduction in eye size (representative eyes shown
in (c), (f)). GSPE treatment does not aﬀect normal-eye development (not shown). (g) The range of ey > R406W phenotypes varies between
trials, so treatment comparisons were made within experiments. The average visual score (0 = no eye, 4 = almost normal eye) ± SEM of
male and female eyes is shown for three independent trials for males and three independent trials for females. The number of ﬂies (n)a n d
P value calculated using a paired t-test on GraphPad online software are indicated beneath each trial. Flies were collected within 5 days of
eclosion. Statistically signiﬁcant improvement (P<. 05) was observed in multiple independent experiments. ∗ indicates P<. 05, ∗∗ indicates
P<. 01, and ∗∗∗ indicates P<. 001. (An excerpt of these images has been presented without data in a review manuscript by the author.)International Journal of Alzheimer’s Disease 3
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Figure 2: GSPE does not inhibit Gal4-mediated expression of GFP. (a) Western-blot analysis of lysates from TubGal4 > GFP ﬂies (created by
crossing TubGal4 ﬂies to UAS-GFP ﬂies) reared from egg deposition either on food supplemented with water (vehicle control) (Lanes 1–3)
or reared on GSPE food (lanes 4–6). Each lysate was prepared from 6 ﬂy heads, and three independent groups of 6 ﬂies per group (lane) are
shown. The same immunoblot was probed ﬁrst with antibodies raised against GFP (upper panel) and then immunoblots were stripped and
reprobed with antiactin antibodies (lower panel). (b) GMR-grim ﬂies have very small, almost absent eyes when reared on control food. (c)
Eye size is not aﬀected when GMR-grim ﬂies are reared on GSPE food.
2.MaterialsandMethods
In this study, MegaNatural grape-seed polyphenolic extract
(GSPE) was provided by Polyphenolics, Inc. (Madera, CA),
as highly puriﬁed (>97% total polyphenols) water-soluble
polyphenolic preparation from Vitis vinifera seeds.
2.1. Drosophila Strains. w; eygal4/SM6-TM6B and GMR-
grimﬂieswereobtainedfromthelabofIKHariharan;w;UAS
R406W andw;Tubgal4(FlyBaseID =FBti0012687)andUAS
g r e e nﬂ u o r e s c e n tp r o t e i n( G F P )(FlyBase ID FBti0012686)
elements were obtained from the Bloomington Stock Center.
2.2. R406W Tau Experiments and Visual Scoring of Eye
Abnormality. eygal4/SM6-TM6B ﬂies were crossed to UAS
R406W ﬂies to generate ey > R406W ﬂies. ey > R406W eggs
were laid in and reared on instant ﬂy medium formula 4–
24 supplemented with 2.8μg/mL GSPE (“GSPE food”), the4 International Journal of Alzheimer’s Disease
concentration used in our previous study [13], or control
food supplemented with an equivalent volume of water
(GSPE solvent, vehicle control).
Flies of the indicated genotypes were examined side by
side under a dissecting scope. Eye regions which formed
no ommatidia (therefore lacked eye tissue completely) were
considered “0 = no eye” and required no comparison. For
eye areas which did form obvious ommatidia/eye tissue,
wild-type control ﬂies were examined at the same time to
establish the “4 = almost wild-type” eye size, shape, and
pattern upper limit. Eyes that formed but did not reach
the “4 = almost wild-type” category were lined up under
the scope by size and grouped into categories based on the
amount of eye tissue present. Because eyes were grouped
side by side under the microscope, relative sizes were easy
to establish. When additional conditions or repeated exper-
iments were examined, representative eyes of each category
from the previous experiments were examined again in
parallel to ensure that the same designations/scoring were
maintained.
2.3. Statistical Analyses. The distribution of eye sizes was
reviewed and found to have negative kurtosis, indicating a
distribution that was more uniform over the range from 0
to 4 than a normal distribution. Negative kurtosis does not
substantially impair analysis of variance.
In addition to overall analysis of variance (with trials
nested within gender and crossed by treatment), separate t-
tests were performed for each trial tested.
3. Results
3.1. GSPE Treatment Improves the Eye Phenotype of ey >
R406W Flies. ey > R406W ﬂies show a range of phenotypes
from no eye to small, abnormal eyes. The reduced size and
abnormal morphology of ey > R406W eyes were improved
by GSPE (F(1,531) = 57.29; P<. 0005). The incidence
of the worst outcomes (visual score of 0 or 1) decreased
upon GSPE treatment in each trial while the incidence of
the best outcomes (visual score of 3 or 4) increased upon
GSPE treatment in each trial. There were also diﬀerences
in the size of male and female eyes (F(1,531) = 58.62;
P<. 0005). Representative eyes are shown in Figures 1(a)–
1(f) ((a)–(c) male; (d)–(f) female). Nonetheless, there was
no interaction between gender and treatment (F(1,531)
= 0.30; P = .59); the diﬀerence between treated and
untreated ﬂies was similar in male and female ﬂies. Separate
t-tests showed that each of the six trials had a statistical
diﬀerence with GSPE treatment characterized by increased
visual scoring relative to untreated controls (Figure 1(g)).
However, within the combinations of gender and treatment,
the trials did not diﬀer signiﬁcantly (F(4,531) = 1.90;
P<. 11).
3.2. GSPE Eﬀects on Gal4/UAS-Mediated Protein Expression.
To address the concern that GSPE could disrupt the pro-
duction of the toxic proteins by the Gal4/UAS system, we
performed control experiments using the Gal4/UAS system
todeterminewhetherGSPEtreatmentpreventsexpressionof
GFPusingaUAS-GFP transgeneandTubGal4 (constitutively
expressed as Gal4). We found no detectable alteration in the
production of GFP both by ﬂuorescent imaging of GFP (not
shown) and by Western analysis (Figure 2(a)).
3.3. GSPE Does Not Aﬀect the Small-Eye Phenotype Caused by
Overexpression of the Proapoptotic Gene Grim. To investigate
if GSPE acts on cell death pathways directly, we examined
theeﬀectsofGSPEtreatmentonﬂiesoverexpressingthepro-
apoptotic gene grim in diﬀerentiating cells in the eye (which
causes a very small eye). GMR-grim ﬂies (which overexpress
the pro-apoptotic gene grim in diﬀerentiating cells in the
eye) laid eggs on control food or GSPE food. GMR-grim ﬂies
rearedentirelyonGSPEfoodshowednoeﬀectofreducedeye
size (Figures 2(b)-2(c)).
4. Discussion
We have demonstrated that GSPE treatment beneﬁts a
distinct Drosophila model of neurodegeneration involving
aggregation in vivo (Figures 1 and 2). GSPE showed no
eﬀect on Gal4-mediated expression of GFP (Figure 2(a)),
indicating that GSPE does not block Gal4/UAS-dependent
gene expression. GSPE had no eﬀect on eye size in GMR-
grim ﬂies (which overexpress in the eye the pro-apoptotic
gene grim which activates caspases and severely reduces eye
size [14]) (Figures 2(b)-2(c)). Thus, although the mech-
anism remains unknown, GSPE-mediated improvements
in the Drosophila eye model likely occur subsequent to
production of the toxic protein but upstream of caspase
activation.
Presently there is no treatment for the devastating pro-
gressive neurodegenerative disorders involving tau abnor-
malities. Continuing investigations suggest that oligomeric
forms of these misfolded proteins may play a seminal role
in disease etiology. Results from our studies show that GSPE
may rescue abnormal tau phenotype in a Drosophila model
of tauopathy. This study is consistent with our previous
study, which provided evidence that GSPE could inhibit
tau peptide aggregation [12] and prevent oligomerization of
Aβ peptides into high molecular weight species in models of
AD-amyloid neuropathology [10, 11]. The study supports
further investigations of GSPE in models of tauopathies,
for example, frontotemporal dementia and CBD, among
others.
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